Axsome Therapeutics Inc (STU:19X)
€ 81.28 -1.42 (-1.74%) Market Cap: 3.94 Bil Enterprise Value: 3.83 Bil PE Ratio: 0 PB Ratio: 40.50 GF Score: 36/100

Axsome Therapeutics Inc - To Discuss the Topline Results of the ADVANCE-1 trial of AXS-05 in Alzheimer's Disease Agitation - Conference Call Transcript

Apr 27, 2020 / 12:00PM GMT
Release Date Price: €87.9 (+28.57%)
Operator

Good morning, ladies and gentlemen, and welcome to Axsome Therapeutics' conference call. (Operator Instructions) As a reminder, today's conference call is being recorded.

I would now like to turn the conference over to your host, Mr. Mark Jacobson, Chief Operating Officer, Axsome Therapeutics. Please go ahead.

Mark L. Jacobson
Axsome Therapeutics, Inc. - COO & Secretary

Thank you, operator. Good morning, everyone, and thank you for joining us on today's conference call to discuss the positive top line results from the ADVANCE-1 Phase II/III trial of AXS-05 in Alzheimer's disease agitation. A press release announcing that AXS-05 achieved the primary endpoint in the trial crossed the wire a short time ago and is available on our website at axsome.com.

During today's conference call, we will be making certain forward-looking statements. These statements may include statements regarding, among other things, the efficacy, safety and intended utilization of our investigational agents; our clinical and nonclinical plans; our plans to present or

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot